Can Immune Therapy Cure Acute Myeloid Leukemia?

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Despite advances in cancer immunotherapy, effective treatments for acute myeloid leukaemia (AML) remain elusive.
• Current immune therapies targeting antigens like CD33, CD123, and CLL-1 demonstrate unconvincing efficacy and significant adverse events in AML.
• AML exhibits limited immune surveillance and a low frequency of neo-antigens, complicating the development of targeted immune therapies.

Purpose of the Study:

• To review the current landscape of immune therapies for acute myeloid leukaemia (AML).
• To evaluate the efficacy and challenges associated with existing and emerging immune-based strategies for AML.
• To explore alternative immune mechanisms, such as graft-versus-leukaemia effects, in the context of AML treatment.

Main Methods:

• Review of existing literature on immune therapies for AML, including antibody-based approaches and cellular therapies.
• Analysis of data on AML incidence in immune-deficient individuals and outcomes in allogeneic haematopoietic cell transplant recipients.
• Examination of emerging strategies such as CAR-T, CAR-NK, and synthetic biology applications in AML immunotherapy.

Main Results:

• Antibody-based therapies targeting CD33, CD123, and CLL-1 have shown limited efficacy and considerable toxicity in AML.
• Allogeneic haematopoietic cell transplantation suggests a potential anti-AML effect, possibly mediated by graft-versus-host disease and graft-versus-leukaemia (GvL) responses.
• Despite ongoing research in CAR-T, CAR-NK, and synthetic biology, no immune therapy currently demonstrates convincing efficacy for AML.

Conclusions:

• Current immune therapies for AML face significant challenges, including lack of specific targets, bone marrow toxicity, and insufficient neo-antigens.
• The graft-versus-leukaemia effect observed in allogeneic transplantation offers a potential avenue for developing effective immune strategies against AML.
• Further research and development are crucial for advancing safe and effective immune-based treatments for acute myeloid leukaemia.